WuXi NextCODE’s Shanghai genomic sequencing facility has been accredited by the College of American Pathologists (CAP), becoming the first such lab in China to be licensed by the State of California to process samples. WuXi NextCODE also has CLIA (Clinial Laboratory Improvement Amendments) certification from the US Centers for Medicare and Medicaid (CMS).
 
“We are a natively global enterprise serving laboratories, hospitals, companies, governments and patients on four continents,” said Hannes Smarason, chief operating officer of WuXi NextCODE, a subsidiary of WuXi AppTec. “Our system is the emerging global standard for querying, storing and collaborating with genomic data, and our global cloud solution similarly leverages our partner DNAnexus’ HIPAA-compliant security. The CAP, CLIA and California accreditation of our sequencing lab demonstrates the same leading standards, enabling us to provide products and services to more customers and to the most demanding standards in every market.”